Female Chromosomes Offer Resilience to Alzheimer’s
UCSF scientists now have evidence from research that women with Alzheimer’s live longer than men with the disease because they have genetic protection from the ravages of the disease.

University of California San Francisco
Give to UCSFUCSF scientists now have evidence from research that women with Alzheimer’s live longer than men with the disease because they have genetic protection from the ravages of the disease.
New research by neuroscientists at the University of Pittsburgh and UC San Francisco revealed that a simple, earbud-like device developed at UCSF that imperceptibly stimulates a key nerve leading to the brain could significantly improve the wearer’s ability to learn the sounds of a new language.
UCSF researchers are taking a closer look at COVID-19’s dizzying array of symptoms to get at the disease’s root causes.
Seniors who can identify smells like roses, turpentine, paint-thinner and lemons, and have retained their senses of hearing, vision and touch, may have half the risk of developing dementia as their peers with marked sensory decline, according to a new UCSF study.
Under a new agreement, Celgene will further invest in the RAN’s state-of-the-art antibody engineering program to expand target discovery from oncology and immunology to include neurology.
In a new study in mice, UCSF researchers investigated what enables neurons in the visual system to respond to context when a stimulus is not available. They found that feedback from higher-order visual centers in the brain has much more influence over our fundamental visual processing than scientists had ever realized.
A new UCSF study in mice has pinpointed a specific pattern of brain waves that underlies the ability to let go of old, irrelevant learned associations to make way for new updates.
UCSF researchers have identified a powerful self-corrective mechanism within synapses that is activated by neurodegeneration and acts to slow down disease progression in animal models of ALS.
A new UCSF study of patients with Parkinson’s disease has revealed a pathway that transmits signals very rapidly between two parts of the human brain to govern the complex act of halting a motion once it’s been initiated.
A simple blood test may soon be able to diagnose patients with two common forms of dementia – Alzheimer’s disease and frontotemporal dementia – and tell the two apart.
A blood test that may eventually be done in a doctor’s office can swiftly reveal if a patient with memory issues has Alzheimer’s disease or mild cognitive impairment and can also distinguish both conditions from frontotemporal dementia.
For a conditioned response to become long-lasting requires brain cells to increase amounts of an insulating material called myelin, which may serve to reinforce and stabilize newly formed neural connections.
Survival may more than double for adults with glioblastoma, if neurosurgeons remove the surrounding tissue as aggressively as they remove the cancerous core of the tumor.
Understanding the biological differences that drive distinct symptoms of Alzheimer’s disease could lead to more personalized patient care and potentially therapies targeted to patients’ individual needs.
English and Italian speakers with dementia-related language impairment experience distinct kinds of speech and reading difficulties based on features of their native languages.
A physically and mentally active lifestyle confers resilience to frontotemporal dementia, even in people whose genetic profile makes the eventual development of the disease virtually inevitable.
Brain imaging of pathological tau-protein reliably predicts the location of future brain atrophy in Alzheimer’s patients a year or more in advance.
A drug that once helped obese adults lose weight, but was withdrawn from the market due to heart risks, may be safe and effective for children with a life-threatening seizure disorder called Dravet syndrome.
With a $106 million gift from the Weill Family Foundation, UC Berkeley, UC San Francisco, and the University of Washington have launched the Weill Neurohub to speed the development of new therapies for diseases and disorders that affect the brain and nervous system.
Adam L. Boxer answers questions about the potential of "basket trials" to accelerate drug development for dementia and neurodegenerative disease.